Format

Send to

Choose Destination
Oncotarget. 2017 Apr 25;8(17):27786-27799. doi: 10.18632/oncotarget.15347.

Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses.

Author information

1
J. Craig Venter Institute, La Jolla, CA, USA.
2
University of California, San Diego, CA, USA.
3
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
4
The Translational Genomics Research Institute, Phoenix, AZ, USA.
5
Yale University, New Haven, CT, USA.

Abstract

High-throughput screening (HTS) strategies and protocols have undergone significant development in the last decade. It is now possible to screen hundreds of thousands of compounds, each exploring multiple biological phenotypes and parameters, against various cell lines or model systems in a single setting. However, given the vast amount of data such studies generate, the fact that they use multiple reagents, and are often technician-intensive, questions have been raised about the variability, reliability and reproducibility of HTS results. Assessments of the impact of the multiple factors in HTS studies could arguably lead to more compelling insights into the robustness of the results of a particular screen, as well as the overall quality of the study. We leveraged classical, yet highly flexible, analysis of variance (ANOVA)-based linear models to explore how different factors contribute to the variation observed in a screening study of four different melanoma cell lines and 120 drugs over nine dosages studied in two independent academic laboratories. We find that factors such as plate effects, appropriate dosing ranges, and to a lesser extent, the laboratory performing the screen, are significant predictors of variation in drug responses across the cell lines. Further, we show that when sources of variation are quantified and controlled for, they contextualize claims of inconsistencies and reveal the overall quality of the HTS studies performed at each participating laboratory. In the context of the broader screening study, we show that our analysis can also elucidate the robust effects of drugs, even those within specific cell lines.

KEYWORDS:

computational modeling; drug screens; high-throughput screening; melanoma; variability

PMID:
28212541
PMCID:
PMC5438608
DOI:
10.18632/oncotarget.15347
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center